Penserra Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Penserra Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,884	Closed	-$221K	–	1271
2023 Q3	$221K	Buy	4,884 +1,023	+26%	+$52.8K	﹤0.01%	714
2023 Q2	$216K	Sell	3,861 -1,319	-25%	-$74.8K	﹤0.01%	770
2023 Q1	$234K	Sell	5,180 -100	-2%	-$4.86K	﹤0.01%	662
2022 Q4	$214K	Sell	5,280 -2,812	-35%	-$149K	﹤0.01%	675
2022 Q3	$528K	Buy	8,092 +6,412	+382%	+$465K	0.02%	413
2022 Q2	$102K	Sell	1,680 -488	-23%	-$28.7K	﹤0.01%	763
2022 Q1	$136K	Buy	+2,168	New	+$136K	﹤0.01%	791
2020 Q4	–	Sell	-598	Closed	-$50K	–	1029
2020 Q3	$50K	Buy	+598	New	+$53K	﹤0.01%	623

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Penserra Capital Management's CRSP Position: Q4 2023 in Review

Penserra Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 4,884 shares — an estimated $221K sold.

Penserra Capital Management first reported a position in CRSP in Q3 2020 and held it in 8 quarters. The position peaked at $528K in Q3 2022. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Penserra Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Penserra Capital Management sold 4,884 CRISPR Therapeutics shares in Q4 2023, an estimated $221K.
Penserra Capital Management first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 8 quarters.
Penserra Capital Management's CRISPR Therapeutics position peaked at $528K in Q3 2022.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.